20.4 C
New York
Thursday, June 18, 2026

Tag: lack

newssourceFORcompanyinformationcontent1marketreleases

NEW GOLD REPORTS SECOND QUARTER 2025 RESULTS

Quarter-Over-Quarter Production Growth Drives Record Free Cash Flow Generation; On-Track to Achieve Annual Guidance (All amounts are in U.S. dollars unless otherwise indicated) TORONTO, July 28,...

NEW GOLD REPORTS SECOND QUARTER 2025 RESULTS

Quarter-Over-Quarter Production Growth Drives Record Free Cash Flow Generation; On-Track to Achieve Annual Guidance (All amounts are in U.S. dollars unless otherwise indicated) TORONTO, July 28,...

Arnold & Itkin Files Lawsuit Against Chevron Following Refinery Explosion

Arnold & Itkin LLP filed a lawsuit against Chevron on behalf of five workers who were seriously injured in a catastrophic explosion at Chevron's...

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November 
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

Best Kratom? Super Speciosa Relaunches Enhanced Watermelon Kratom Tincture in 2025

As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency 
As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency

Bar Partners Modernizes Bar Entertainment Nationwide with Verizon Connectivity

Introducing a zero-cost, fully connected entertainment model driving revenue growth for bars and venues nationwide AUSTIN, Texas, July 23, 2025 /PRNewswire/ -- Bar Partners, North America's...

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

Portland General Electric Announces Second Quarter 2025 Results

Second quarter financial results reflect significant demand growth from data center customers, driving 16.5% industrial load growth quarter-over-quarterAdvancing recovery of the Seaside battery, distribution...

Informal caregivers in Singapore seen as undertrained and overwhelmed

Despite nearly all professional caregivers agreeing that informal caregivers can help bridge the demand of caregiving in Singapore to a certain extent (30% large,...

Regenx Announces Delay in Filing of Annual Filings and Application for Management Cease Trade Order

EDMONTON, Alberta, July 24, 2025 (GLOBE NEWSWIRE) -- Regenx Tech Corp., (the "Corporation" or "Regenx") (CSE: RGX) (OTCQB: RGXT) (FSE: YRS WKN: A2DSW3) announces that as a result in delays in the completion of its audit, the Corporation will be unable to meet the filing deadline of July 29, 2025, for filing of the following continuous disclosure documents (collectively, the “Annual Filings”):

DELTA DENTAL OF COLORADO NAMES KEITH W. PHILLIPS CHIEF FINANCIAL OFFICER

Phillips brings 20+ years of experience in finance across various industries DENVER, July 24, 2025 /PRNewswire/ -- Today, Delta Dental of Colorado (DDCO) announced the...

Meridian Corporation Reports Second Quarter 2025 Results and Announces a Quarterly Dividend of $0.125 per Common Share

MALVERN, Pa., July 24, 2025 (GLOBE NEWSWIRE) -- Meridian Corporation (Nasdaq: MRBK) today reported:

Sugar Land Medical Weight Loss Expert, Dr. Adelola Ashaye, Launches Metabolic Wellness & Healthy Weight Program at InTouch Primary Care

Dr. Adelola Ashaye has launched Metabolic Wellness & Healthy Weight Program at InTouch Primary Care, offering a personalized, medically guided approach to sustainable weight loss...

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLack

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers